Following excellent efficacy secukinumab has shown in clinical trials, two other humanized monoclonal IL-17A antibodies ixekizumab and netakimab, and an IL-17A receptor antagonist brodalumab, gained FDA approval for treatment of psoriasis and axial spondiloarthritis (56–58). This evidence concerns the gene IL17A and psoriasis.